How to Ethically and Effectively Publish Clinical Trial Results in Scientific Journals

Introduction: From Data to Peer-Reviewed Impact

Publishing the results of clinical trials in peer-reviewed journals is a crucial step in the research lifecycle. It transforms raw data into publicly available evidence, informs medical decision-making, and validates the ethical commitment made to trial participants. However, publication involves more than just writing a manuscript—it requires adherence to transparency policies, ethical standards, and scientific rigor.

Today’s regulatory and editorial landscape is stricter than ever. Journals—particularly those aligned with the International Committee of Medical Journal Editors (ICMJE)—now demand prospective registration, full results disclosure, and compliance with reporting standards such as CONSORT. This tutorial explores how clinical trial sponsors and investigators can navigate the publication process successfully and ethically.

Trial Registration and ICMJE Publication Policy

As a prerequisite for publication in major medical journals, trials must be prospectively registered in a publicly accessible registry approved by the WHO ICTRP (e.g., ClinicalTrials.gov, CTRI, ISRCTN). The ICMJE mandates this to prevent selective reporting and publication bias.

Key expectations include:

• Registration before the first participant is enrolled
• Use of a WHO-compliant registry
• Inclusion of the Trial Registration Number (TRN) in the manuscript

Failure to meet these conditions may lead to automatic manuscript rejection, regardless of scientific merit.

Choosing the Right Journal for Publication

Choosing the right target journal affects not only visibility but also the peer-review timeline and acceptance chances. Consider the following criteria:

• Scope alignment: Match the journal’s audience and therapeutic area
• Impact factor and indexing: Ensure indexing in PubMed, Scopus, or Web of Science
• Open access policies: Consider funder mandates for OA publishing
• Disclosure and ethics policies: Review the journal’s stance on registration, data sharing, and conflicts of interest

Top journals like NEJM, The Lancet, BMJ, and JAMA have detailed author guidelines and expect full transparency from submission.

Manuscript Structure: Following CONSORT Guidelines

The CONSORT (Consolidated Standards of Reporting Trials) statement provides a checklist and flow diagram to guide the transparent reporting of randomized controlled trials. Common manuscript sections include:

• Abstract: Structured summary with trial ID
• Introduction: Rationale, objectives, and trial design summary
• Methods: Eligibility criteria, interventions, randomization, blinding
• Results: Participant flow, outcomes, adverse events, statistical analyses
• Discussion: Interpretation, limitations, generalizability, and ethical context

Manuscripts should be concise, evidence-based, and reference all pre-registered outcomes and deviations.

Handling Negative or Inconclusive Results

One of the biggest ethical lapses in trial transparency is failure to publish negative or inconclusive results. However, many journals explicitly encourage such submissions because they:

• Prevent unnecessary duplication of research
• Reduce publication bias
• Support accurate systematic reviews and meta-analyses

Authors should resist the urge to suppress disappointing findings. Instead, contextualize them in the discussion section and focus on scientific learning and future implications.

Addressing Authorship and Conflict of Interest

Authorship must reflect substantial contribution to the conception, design, data analysis, or manuscript drafting. Most journals follow ICMJE authorship criteria:

• Contribution to trial design or data collection
• Drafting or revising the manuscript
• Approval of the final version
• Accountability for content accuracy

Disclosures of financial or personal conflicts of interest are mandatory. Failure to do so can lead to retraction or reputational harm.

Preprint Servers and Early Data Sharing

Increasingly, trial results are shared via preprint servers such as medRxiv or bioRxiv. While these are not peer-reviewed, they allow early access to findings and support open science. However:

• Journals may have policies regarding prior dissemination—always check
• Clearly label the version as a preprint in the manuscript submission
• Avoid media press releases until after peer-review, unless permitted

Preprints are useful for public health emergencies (e.g., COVID-19) or when rapid dissemination is critical.

Best Practices for a Successful Submission

To maximize publication success:

• Include the trial registration number in the title page and abstract
• Cross-check outcomes with registered protocol—explain deviations
• Use reporting checklists (e.g., CONSORT, SPIRIT, STROBE)
• Submit to a journal with a history of publishing similar trials
• Ensure all disclosures and acknowledgments are included

Consider submitting graphical abstracts, plain language summaries, and data availability statements to improve transparency and reach.

Conclusion: Publishing Is a Transparency Milestone

Publishing clinical trial results in peer-reviewed journals is both a scientific obligation and a regulatory requirement. With expectations rising around transparency, ethical authorship, and data accessibility, sponsors must treat publication planning as a core component of trial design.

By following registry policies, reporting standards, and journal requirements, researchers can ensure their findings contribute to the evidence base, respect participant contributions, and stand up to public and scientific scrutiny.